Search

Your search keyword '"Lüftner, Diana"' showing total 335 results
Start Over Author "Lüftner, Diana" Language english
335 results on '"Lüftner, Diana"'

1. The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype

Author

Ziegler, Philipp, Hartkopf, Andreas D., Wallwiener, Markus, Häberle, Lothar, Kolberg, Hans-Christian, Hadji, Peyman, Tesch, Hans, Ettl, Johannes, Lüftner, Diana, Müller, Volkmar, Michel, Laura L., Belleville, Erik, Wimberger, Pauline, Hielscher, Carsten, Huebner, Hanna, Uhrig, Sabrina, Wurmthaler, Lena A., Hack, Carolin C., Mundhenke, Christoph, Kurbacher, Christian, Fasching, Peter A., Wuerstlein, Rachel, Untch, Michael, Janni, Wolfgang, Taran, Florin-Andrei, Lux, Michael P., Wallwiener, Diethelm, Brucker, Sara Y., Fehm, Tanja N., Schneeweiss, Andreas, and Goossens, Chloë

Published
2024
Full Text
View/download PDF

2. Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer

Author

Fasching, Peter A., Hu, Chunling, Hart, Steven N., Ruebner, Matthias, Polley, Eric C., Gnanaolivu, Rohan D., Hartkopf, Andreas D., Huebner, Hanna, Janni, Wolfgang, Hadji, Peyman, Tesch, Hans, Uhrig, Sabrina, Ettl, Johannes, Lux, Michael P., Lüftner, Diana, Wallwiener, Markus, Wurmthaler, Lena A., Goossens, Chloë, Müller, Volkmar, Beckmann, Matthias W., Hein, Alexander, Anetsberger, Daniel, Belleville, Erik, Wimberger, Pauline, Untch, Michael, Ekici, Arif B., Kolberg, Hans-Christian, Hartmann, Arndt, Taran, Florin-Andrei, Fehm, Tanja N., Wallwiener, Diethelm, Brucker, Sara Y., Schneeweiss, Andreas, Häberle, Lothar, and Couch, Fergus J.

Published
2024
Full Text
View/download PDF

3. Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference—a German expert perspective

Author

Krug, David, Banys-Paluchowski, Maggie, Brucker, Sara Y., Denkert, Carsten, Ditsch, Nina, Fasching, Peter A., Haidinger, Renate, Harbeck, Nadia, Heil, Jörg, Huober, Jens, Jackisch, Christian, Janni, Wolfgang, Kolberg, Hans-Christian, Loibl, Sibylle, Lüftner, Diana, van Mackelenbergh, Marion, Radosa, Julia C., Reimer, Toralf, Welslau, Manfred, Würstlein, Rachel, Untch, Michael, and Budach, Wilfried

Published
2024
Full Text
View/download PDF

6. PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant

Author

Degenhardt, Tom, Fasching, Peter A., Lüftner, Diana, Müller, Volkmar, Thomssen, Christoph, Schem, Christian, Witzel, Isabell, Decker, Thomas, Tesch, Hans, Kümmel, Sherko, Uleer, Christoph, Wuerstlein, Rachel, Hoffmann, Oliver, Warm, Mathias, Marschner, Norbert, Schinköthe, Timo, Kates, Ronald E., Schumacher, Johannes, Otremba, Burkhard, Zaiss, Matthias, Harbeck, Nadia, and Schmidt, Marcus

Published
2023
Full Text
View/download PDF

7. Return of individual genomic research results within the PRAEGNANT multicenter registry study

Author

Huebner, Hanna, Ruebner, Matthias, Kurbacher, Christian, Hadji, Peyman, Hartkopf, Andreas D., Lux, Michael P., Huober, Jens, Uhrig, Sabrina, Taran, Florin-Andrei, Overkamp, Friedrich, Tesch, Hans, Häberle, Lothar, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Hein, Alexander, Belleville, Erik, Untch, Michael, Janni, Wolfgang, Fehm, Tanja N., Kolberg, Hans-Christian, Wallwiener, Diethelm, Brucker, Sara Y., Schneeweiss, Andreas, Ettl, Johannes, Fasching, Peter A., and Michel, Laura L.

Published
2023
Full Text
View/download PDF

9. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study.

Author

Lüftner, Diana, Schuetz, Florian, Schneeweiss, Andreas, Hartkopf, Andreas, Bloch, Wilhelm, Decker, Thomas, Uleer, Christoph, Stötzer, Oliver, Foerster, Frank, Schmidt, Marcus, Mundhenke, Christoph, Tesch, Hans, Jackisch, Christian, Fischer, Thomas, Kreuzeder, Julia, Guderian, Gernot, and Fasching, Peter A.

Subjects
METASTATIC breast cancer, PROPORTIONAL hazards models
Abstract

BRAWO, a real‐world study, assessed the efficacy, quality of life (QoL) and safety of EVE + EXE in postmenopausal women with HR+/HER2– advanced breast cancer (ABC) in routine clinical practice. Postmenopausal women with HR+/HER2‐ABC with recurrence or progression after a NSAI were included. Primary Observation parameters included the evaluation of the effectiveness of EVE + EXE. A multivariate‐analysis using Cox proportional hazard model was built to identify predictors of progression. Overall, 2100 patients were enrolled (August 2012–December 2017); 2074 were evaluable for efficacy and safety analyses. Majority of patients (60.6%) received EVE + EXE as first (28.7%) or second‐line (31.9%) therapy. Visceral metastases were present in 54.1% patients. Median progression‐free survival (mPFS) reported as 6.6 months (95%CI: 6.3–7.0). Multivariate‐analysis in a subset of patients (n = 1837) found higher body mass index (BMI) and non‐visceral metastases to be independent predictors of favorable PFS. Patients with a BMI of 20 to <25 had a mPFS of 6.0 (95%CI: 5.4–6.4) and those with a BMI ≥30 had mPFS of 8.5 (95%CI: 6.9–9.9). 41.2% patients achieved stable disease and 7.3% partial response. No major changes were observed QoL; 86.4% patients received stomatitis prophylaxis and 41.4% experienced EVE related AEs of stomatitis, mainly low grade. AEs occurred in 91.2% of patients, of which stomatitis (42.6%) and fatigue (19.8%) were most frequent. The BRAWO study provides real‐world evidence of efficacy and safety of EVE + EXE in patients with HR+, HER2− ABC. A high BMI and the absence of visceral metastases were independent predictors of PFS in this cohort of patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer.

Author

Würstlein, Rachel, Kolberg, Hans-Christian, Hartkopf, Andreas D., Fehm, Tanja N., Welslau, Manfred, Schütz, Florian, Fasching, Peter A., Janni, Wolfgang, Witzel, Isabell, Thomssen, Christoph, Krückel, Annika, Belleville, Erik, Lüftner, Diana, Untch, Michael, Thill, Marc, Hörner, Manuel, Tesch, Hans, Ditsch, Nina, Lux, Michael P., and Aktas, Bahriye

Published
2024
Full Text
View/download PDF

13. Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry.

Author

Hartkopf, Andreas D., Walter, Christina B., Kolberg, Hans-Christian, Hadji, Peyman, Tesch, Hans, Fasching, Peter A., Ettl, Johannes, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Belleville, Erik, Huebner, Hanna, Uhrig, Sabrina, Goossens, Chloë, Link, Theresa, Hielscher, Carsten, Mundhenke, Christoph, Kurbacher, Christian, and Wuerstlein, Rachel

Published
2024
Full Text
View/download PDF

14. CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs.

Author

Schneeweiss, Andreas, Brucker, Sara Y., Huebner, Hanna, Volmer, Lea L., Hack, Carolin C., Seitz, Katharina, Ruebner, Matthias, Heublein, Sabine, Thewes, Verena, Lüftner, Diana, Lux, Michael P., Jurhasz-Böss, Ingolf, Taran, Florin-Andrei, Wimberger, Pauline, Anetsberger, Daniel, Beierlein, Milena, Schmidt, Marcus, Radosa, Julia, Müller, Volkmar, and Janni, Wolfgang

Published
2024
Full Text
View/download PDF

15. Discussion of ABC7 Consensus and German Recommendations.

Author

Untch, Michael, Ditsch, Nina, Fasching, Peter A., Busch, Steffi, Ettl, Johannes, Haidinger, Renate, Harbeck, Nadia, Jackisch, Christian, Lüftner, Diana, Müller, Lothar, Ruckhäberle, Eugen, Schumacher-Wulf, Eva, Thomssen, Christoph, Wuerstlein, Rachel, and Müller, Volkmar

Published
2024
Full Text
View/download PDF

17. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis

Author

Fasching, Peter A., Hartkopf, Andreas D., Gass, Paul, Häberle, Lothar, Akpolat-Basci, Leyla, Hein, Alexander, Volz, Bernhard, Taran, Florin-Andrei, Nabieva, Naiba, Pott, Birgit, Overkamp, Friedrich, Einarson, Hanna, Hadji, Peyman, Tesch, Hans, Ettl, Johannes, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Janni, Wolfgang, Fehm, Tanja N., Schneeweiss, Andreas, Untch, Michael, Pott, Dirk, Lux, Michael P., Geyer, Thomas, Liedtke, Cornelia, Seeger, Harald, Wetzig, Sarah, Hartmann, Arndt, Schulz-Wendtland, Rüdiger, Belleville, Erik, Wallwiener, Diethelm, Beckmann, Matthias W., Brucker, Sara Y., and Kolberg, Hans-Christian

Published
2019
Full Text
View/download PDF

18. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

Author

Huebner, Hanna, Kurbacher, Christian M., Kuesters, Geoffrey, Hartkopf, Andreas D., Lux, Michael P., Huober, Jens, Volz, Bernhard, Taran, Florin-Andrei, Overkamp, Friedrich, Tesch, Hans, Häberle, Lothar, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Belleville, Erik, Ruebner, Matthias, Untch, Michael, Fasching, Peter A., Janni, Wolfgang, Fehm, Tanja N., Kolberg, Hans-Christian, Wallwiener, Diethelm, Brucker, Sara Y., Schneeweiss, Andreas, and Ettl, Johannes

Published
2020
Full Text
View/download PDF

19. ABC7 Consensus: Assessment by a German Group of Experts.

Author

Ditsch, Nina, Untch, Michael, Fasching, Peter A., Busch, Steffi, Ettl, Johannes, Haidinger, Renate, Jackisch, Christian, Lüftner, Diana, Müller, Lothar, Müller, Volkmar, Ruckhäberle, Eugen, Schumacher-Wulf, Eva, Thomssen, Christoph, Harbeck, Nadia, and Würstlein, Rachel

Subjects
BREAST tumor treatment, CONSENSUS (Social sciences), MEETINGS, CONFERENCES & conventions, MENINGEAL cancer, METASTASIS, ATTITUDES of medical personnel, CONTRACEPTION, BRAIN tumors
Abstract

Background: The "International Consensus Conference for Advanced Breast Cancer" was initiated more than 10 years ago. The rationale was to standardize treatment of advanced breast cancer (ABC) based on available evidence and to ensure that all ABC patients worldwide receive adequate treatment and access to new therapies. Topics of ABC7: The 7th International Consensus Conference for ABC (ABC7) took place from November 9 to 11, 2023 – as in previous years in Lisbon/Portugal. ABC7 focused not only on metastatic disease but also on locally advanced and inflammatory breast cancer. Special topics were the management of oligometastatic disease, leptomeningeal disease, brain metastases, and pregnant women with ABC. Due to the current situation worldwide, there was a special interest to patients living in conflict zones. As in previous years, patient advocates from around the world were integrated into the ABC conference and had a major input to the consensus. Rationale for the Manuscript: A German breast cancer expert panel comments on the voting results of the ABC7 panelists regarding their relevance for routine clinical practice in Germany. As with previous meetings, the ABC7 votes focused on modified or new statements. Regarding the statements not modified for the ABC7 consensus, they are discussed in the published manuscript from 2021 in which the German experts commented on the ABC6 consensus. The German comments are always based on the current recommendations of the "Breast Committee" of the Gynecological Oncology Working Group (Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Mamma). Box 1. ABC7 Panelists: 1-Fatima Cardoso, PT (chair) 2-Eric P. Winer, US (honorary chair) 3-Larry Norton, US (honorary chair) 4-Alberto Costa, CH/IT (honorary chair, not in presence) 5-Eva Schumacher-Wulf, DE (co-chair, patient advocate) 6-Sandra Ximena Franco Millan, CO (scientific committee) 7-Karen Gelmon, CA (scientific committee) 8-JosephGligorov, FR (scientific committee) 9-Volkmar Mueller, DE (scientific committee) 10-Birgitte V. Offersen, DK (scientific committee) 11-Sandra Swain, US (scientific committee) 12-Matti S. Aapro, CH 13-Jyoti Bajpai, IN 14-Carlos H. Barrios, BR 15-Laura Biganzoli, IT 16-Maria João Cardoso, PT 17-Lisa A Carey, US 18-Mariana Chavez MacGregor, US 19-Runcie CW Chidebe, NG (patient advocate) 20-Javier Cortés, ES 21-Rebecca Dent, SG 22-Nagi S. El Saghir, LB 23-Alexandru Eniu, CH 24-Lesley Fallowfield, UK (psycho-oncologist) 25-Prudence A. Francis, AU 26-Jenny Gilchrist, AU 27-William Gradishar, US 28-Nadia Harbeck, DE 29-Xichun Hu, CN 30-Ranjit Kaur, MY (patient advocate) 31-Belinda Kiely, AU 32-Sung-Bae Kim, KR 33-Marion Kuper-Hommel, NZ 34-Frédéric E. Lecouvet, BE 35-Ginny Mason, US (patient advocate) 36-Claire Myerson, UK (patient advocate) 37-Silvia Neciosup, PE 38-Shinji Ohno, JP 39-Shani Paluch-Shimon, IL 40-Ann Partridge, US 41-Frédérique Penault-Llorca, FR 42-Hope S. Rugo, US 43-Elzbieta Senkus, PL 44-Peter Vuylsteke, BW 45-Theresa Wiseman, UK (nurse) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Update Breast Cancer 2022 Part 6 : advanced-stage breast cancer

Author

Lüftner, Diana, Thomssen, Christoph, and [Und Viele Weitere]

Abstract

Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody–drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody–drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.

Published
2023
Full Text
View/download PDF

23. Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network

Author

Fremd, Carlo, Hack, Carolin C., Schneeweiss, Andreas, Rauch, Geraldine, Wallwiener, Diethelm, Brucker, Sara Yvonne, Taran, Florin-Andrei, Hartkopf, Andreas, Overkamp, Friedrich, Tesch, Hans, Fehm, Tanja, Hadji, Peyman, Janni, Wolfgang, Lüftner, Diana, Lux, Michael P., Müller, Volkmar, Ettl, Johannes, Belleville, Erik, Sohn, Christof, Schuetz, Florian, Beckmann, Matthias M., Fasching, Peter A., and Wallwiener, Markus

Published
2017
Full Text
View/download PDF

25. Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients

Author

Hein, Alexander, Gass, Paul, Walter, Christina Barbara, Taran, Florin-Andrei, Hartkopf, Andreas, Overkamp, Friedrich, Kolberg, Hans-Christian, Hadji, Peyman, Tesch, Hans, Ettl, Johannes, Wuerstlein, Rachel, Lounsbury, Debra, Lux, Michael P., Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Belleville, Erik, Janni, Wolfgang, Fehm, Tanja N., Wallwiener, Diethelm, Ganslandt, Thomas, Ruebner, Matthias, Beckmann, Matthias W., Schneeweiss, Andreas, Fasching, Peter A., and Brucker, Sara Y.

Published
2016
Full Text
View/download PDF

26. Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus

Author

Untch, Michael, Fasching, Peter A., Brucker, Sara Y., Budach, Wilfried, Denkert, Carsten, Haidinger, Renate, Huober, Jens, Jackisch, Christian, Janni, Wolfgang, Kolberg-Liedtke, Cornelia, Krug, David, Kühn, Thorsten, Loibl, Sibylle, Lüftner, Diana, Müller, Volkmar, Schneeweiss, Andreas, Thill, Marc, Harbeck, Nadia, and Thomssen, Christoph

Subjects
St. Gallen Consensus 2021, targeted therapy, Strahlentherapie, (neo)adjuvante Systemtherapie, zielgerichtete Therapie, (neo)adjuvant systemic therapy, surgery, St.-Gallen-Konsensus 2021, Review/Übersicht, GebFra Science, early breast cancer, skin and connective tissue diseases, frühes Mammakarzinom, radiotherapy, Operation
Abstract

This year's 17th St. Gallen (SG) Consensus Conference on the Treatment of Patients with Early Breast Cancer (SG-BCC) with the title "Customizing local and systemic therapies for women with early breast cancer" focused on the challenge of targeting the treatment of early breast cancer more specifically to the individual disease situation of each patient. As in previous years, a German working group of leading breast cancer experts discussed the results of the international SG-BCC 2021 in the context of the German guideline. It is helpful to compare the SG recommendations with the recently updated treatment recommendations of the Breast Commission of the German Working Group on Gynaecological Oncology (Arbeitsgemeinschaft Gynäkologische Onkologie e. V., AGO) and the S3 guideline because the SG-BCC panel comprised experts from different countries, which is why country-specific aspects can be incorporated into the SG recommendations. The German treatment recommendations of the AGO and the S3 guideline are based on current evidence. Nevertheless, any therapeutic decision must always undergo a risk-benefit analysis for the specific situation and to be discussed with the patient.

Published
2021

27. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

Author

Schneeweiss, Andreas, Ettl, Johannes, Lüftner, Diana, Beckmann, Matthias W., Belleville, Erik, Fasching, Peter A., Fehm, Tanja N., Geberth, Matthias, Häberle, Lothar, Hadji, Peyman, Hartkopf, Andreas D., Hielscher, Carsten, Huober, Jens, Ruckhäberle, Eugen, Janni, Wolfgang, Kolberg, Hans Christian, Kurbacher, Christian M., Klein, Evelyn, Lux, Michael P., Müller, Volkmar, Nabieva, Naiba, Overkamp, Friedrich, Tesch, Hans, Laakmann, Elena, Taran, Florin-Andrei, Seitz, Julia, Thomssen, Christoph, Untch, Michael, Wimberger, Pauline, Wuerstlein, Rachel, Volz, Bernhard, Wallwiener, Diethelm, Wallwiener, Markus, and Brucker, Sara Y.

Subjects
Endocrine therapy, Antineoplastic Agents, Hormonal, Receptor, ErbB-2, Antineoplastic Agents, Breast Neoplasms, Palbociclib, lcsh:RC254-282, Germany, Ribociclib, Antineoplastic Combined Chemotherapy Protocols, Product Surveillance, Postmarketing, CDK4/6, Humans, Chemotherapy, ddc:610, Prospective Studies, Registries, Protein Kinase Inhibitors, neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Progression-Free Survival, Abemaciclib, Treatment Outcome, Receptors, Estrogen, Metastatic, Female, Original Article, Advanced breast cancer, Receptors, Progesterone, Corrigendum
Abstract

Purpose Treatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients with advanced hormone receptor–positive, HER2-negative (HR + HER2–) breast cancer (BC). However, real-world data on the implementation of therapy usage, efficacy, and toxicity have not yet been reported. Methods The PRAEGNANT registry was used to identify advanced HR + HER2– BC patients (n = 1136). The use of chemotherapy, ET, everolimus + ET, and CDK4/6i + ET was analyzed for first-line, second-line, and third-line therapy. Progression-free survival (PFS) and overall survival (OS) were also compared between patients treated with CDK4/6i + ET and ET monotherapy. Also toxicity was assessed. Results CDK4/6i + ET use increased from 38.5% to 62.7% in the first 2 years after CDK4/6i treatment became available (November 2016). Chemotherapy and ET monotherapy use decreased from 2015 to 2018 from 42.2% to 27.2% and from 53% to 9.5%, respectively. In this early analysis no statistically significant differences were found comparing CDK4/6i + ET and ET monotherapy patients with regard to PFS and OS. Leukopenia was was seen in 11.3% of patients under CDK4/6i + ET and 0.5% under ET monotherapy. Conclusions In clinical practice, CDK4/6i + ET has been rapidly implemented. A group of patients with a more unfavorable prognosis was possibly treated in the real-world setting than in the reported randomized clinical trials. The available data suggest that longer follow-up times and a larger sample size are required in order to identify differences in survival outcomes. Studies should be supported that investigate whether chemotherapy can be avoided or delayed in this patient population by using CDK4/6i + ET., Highlights • CDK4/6i + ET use increased from 39% to 63% after becoming available. • Chemotherapy and ET monotherapy use decreased from 42% to 27% and 53%–10%. • There was no difference between CDK4/6i + ET and ET monotherapy regarding PFS and OS.

Published
2020

28. Update Breast Cancer 2022 Part 3 : Early-Stage Breast Cancer

Author

Fehm, Tanja N., Welslau, Manfred, Müller, Volkmar, Lüftner, Diana, Schütz, Florian, Fasching, Peter A., Janni, Wolfgang, Thomssen, Christoph, Witzel, Isabell, Belleville, Erik, Untch, Michael, Thill, Marc, Tesch, Hans, Ditsch, Nina, Lux, Michael P., Aktas, Bahriye, Banys-Paluchowski, Maggie, Schneeweiss, Andreas, Kolberg-Liedtke, Cornelia, Hartkopf, Andreas D., Wöckel, Achim, Kolberg, Hans-Christian, Harbeck, Nadia, and Stickeler, Elmar

Subjects
Medizin
Abstract

This review summarizes recent developments in the prevention and treatment of patients with early-stage breast cancer. The individual disease risk for different molecular subtypes was investigated in a large epidemiological study. With regard to treatment, new data are available from long-term follow-up of the Aphinity study, as well as new data on neoadjuvant therapy with atezolizumab in HER2-positive patients. Biomarkers, such as residual cancer burden, were investigated in the context of pembrolizumab therapy. A Genomic Grade Index study in elderly patients is one of a group of studies investigating the use of modern multigene tests to identify patients with an excellent prognosis in whom chemotherapy may be avoided. These and other aspects of the latest developments in the diagnosis and treatment of breast cancer are described in this review.

Published
2022

29. Update breast cancer 2022 part 2 – advanced stage breast cancer

Author

Müller, Volkmar, Welslau, Manfred, Lüftner, Diana, Schütz, Florian, Stickeler, Elmar, Fasching, Peter A., Janni, Wolfgang, Thomssen, Christoph, Witzel, Isabell, Fehm, Tanja N., Belleville, Erik, Bader, Simon, Seitz, Katharina, Untch, Michael, Thill, Marc, Tesch, Hans, Ditsch, Nina, Lux, Michael P., Aktas, Bahriye, Banys-Paluchowski, Maggie, Schneeweiss, Andreas, Harbeck, Nadia, Würstlein, Rachel, Hartkopf, Andreas D., Kolberg, Hans-Christian, and Wöckel, Achim

Subjects
Maternity and Midwifery, Obstetrics and Gynecology, ddc:610
Abstract

Geburtshilfe und Frauenheilkunde 82(6), 590-600 (2022). doi:10.1055/a-1811-6148, Published by Thieme, Stuttgart ; New York, NY

Published
2022
Full Text
View/download PDF

32. Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer.

Author

Fehm, Tanja N., Welslau, Manfred, Müller, Volkmar, Lüftner, Diana, Schütz, Florian, Fasching, Peter A., Janni, Wolfgang, Thomssen, Christoph, Witzel, Isabell, Beierlein, Milena, Belleville, Erik, Untch, Michael, Thill, Marc, Tesch, Hans, Ditsch, Nina, Lux, Michael P., Aktas, Bahriye, Banys-Paluchowski, Maggie, Kolberg-Liedtke, Cornelia, and Hartkopf, Andreas D.

Published
2023
Full Text
View/download PDF

33. Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus

Author

Untch, Michael, Thomssen, Christoph, Bauerfeind, Ingo, Braun, Michael, Brucker, Sara Y., Felberbaum, Ricardo, Hagemann, Friederike, Haidinger, Renate, Hönig, Arnd, Huober, Jens, Jackisch, Christian, Kolberg, Hans-Christian, Kolberg-Liedtke, Cornelia, Kühn, Thorsten, Lüftner, Diana, Maass, Nicolai, Reimer, Toralf, Schneeweiss, Andreas, Schumacher-Wulf, Eva, Schütz, Florian, Thill, Marc, Wuerstlein, Rachel, Fasching, Peter A., and Harbeck, Nadia

Subjects
neoadjuvant treatment, axilla, lokoregionäre Therapie, Systemtherapie, St.-Gallen-Konsensus 2019, St. Gallen consensus 2019, locoregional therapy, Review/Übersicht, GebFra Science, early breast cancer, neoadjuvante Therapie, frühes Mammakarzinom, systemic therapy
Abstract

The results of the international St. Gallen Consensus Conference for the treatment of patients with primary breast cancer were discussed this year by a working group of leading breast cancer experts in view of the therapy recommendations for everyday clinical practice in Germany. Three of the breast cancer experts are also members of this year's St. Gallen panel. The comparison of the St. Gallen recommendations with the annually updated treatment recommendations of the AGO 2019 as well as the S3 guideline is useful, since the recommendations of the St. Gallen panel represent the opinions of experts from various countries and disciplines. The recommendations of the S3 guideline and AGO are based on evidence-based research of the literature. This year's 16th St. Gallen conference featured the motto "Magnitude of clinical benefit". In addition to the evidence-based data, each therapeutic decision must also undergo a benefit/risk assessment of the patient's individual situation and be discussed with the patient.

Published
2019

37. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT.

Author

Engler, Tobias, Fasching, Peter A., Lüftner, Diana, Hartkopf, Andreas D., Müller, Volkmar, Kolberg, Hans-Christian, Hadji, Peyman, Tesch, Hans, Häberle, Lothar, Ettl, Johannes, Wallwiener, Markus, Beckmann, Matthias W., Hein, Alexander, Belleville, Erik, Uhrig, Sabrina, Wimberger, Pauline, Hielscher, Carsten, Kurbacher, Christian M., Wuerstlein, Rachel, and Untch, Michael

Published
2022
Full Text
View/download PDF

38. Advanced Breast Cancer.

Author

Untch, Michael, Fasching, Peter A., Haidinger, Renate, Harbeck, Nadia, Jackisch, Christian, Lüftner, Diana, Müller, Volkmar, Schumacher-Wulf, Eva, Würstlein, Rachel, and Thomssen, Christoph

Published
2022
Full Text
View/download PDF

39. Ribecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole : Final results

Author

Reinisch, Mattea, Nusch, Arndt, Decker, Thomas, Hartkopf, Andreas, Heinrich, Bernhard J., Kurbacher, Christian M., Fuchs, Roswitha, Tesch, Hans, Krabisch, Petra, Brucker, Sara Y., Fehm, Tanja, Janni, Wolfgang, Kuemmel, Sherko, Lüftner, Diana, Schneeweiss, Andreas, Schuler, Martin, Voges, Claudia, Schubert, Jörg, and Fasching, Peter A.

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2021

40. Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer : Third interim analysis from the RIBANNA study

Author

Wöckel, Achim, Brucker, Cosima, Decker, Thomas, Falbrede, Jörg, Forstbauer, Helmut, Göhler, Thomas, Hoffmann, Oliver, Jackisch, Christian, Janssen, Jan, Köhler, Andreas, Lüdtke-Heckenkamp, Kerstin, Lüftner, Diana, Marmé, Frederik, Nusch, Arnd, Reimer, Toralf, Roos, Christian, Schmidt, Marcus, Weide, Rudolf, and Fasching, Peter

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2021

44. Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer.

Author

Aktas, Bahriye, Fehm, Tanja N., Welslau, Manfred, Müller, Volkmar, Lüftner, Diana, Schütz, Florian, Fasching, Peter A., Janni, Wolfgang, Thomssen, Christoph, Witzel, Isabell, Belleville, Erik, Untch, Michael, Thill, Marc, Tesch, Hans, Ditsch, Nina, Lux, Michael P., Banys-Paluchowski, Maggie, Kolberg-Liedtke, Cornelia, Hartkopf, Andreas D., and Wöckel, Achim

Published
2022
Full Text
View/download PDF

45. Prophylaxis of Neutropenia with Lipegfilgrastim in Breast Cancer Patients with Dose-Dense Chemotherapy: Results of a Noninterventional Study on Therapeutic Routine in Germany (NADENS).

Author

Kiechle, Marion, Schem, Christian, Lüftner, Diana, Hipp, Joachim, Stetzer, Eva, and Köhler, Uwe

Subjects
RESEARCH, GRANULOCYTE-colony stimulating factor, DRUG tolerance, CANCER chemotherapy, NEUTROPENIA, CANCER patients, TREATMENT effectiveness, DRUG side effects, BREAST tumors, LONGITUDINAL method
Abstract

Introduction: Noninterventional study (NIS) on application and effectiveness of primary G-CSF prophylaxis with lipegfilgrastim in primary breast cancer patients undergoing dose-dense (dd) or intense-dose-dense (idd) chemotherapy (CTx) regimen in daily clinical practice. Methods: Prospective, multicenter, single-arm, NIS in 41 private practices and 27 hospitals in Germany. Results: Data analysis of 282 patients with a mean age of 49 years (93.6% of patients <65 years) was performed. Hormone receptor status was triple negative in 29.8% of patients, and 81.9% of patients were HER2 negative. A total of 73.8% of patients received "EC dd → taxane CTx." Patients received lipegfilgrastim prophylaxis in 97.5% of 1,121 documented dd/idd cycles. Overall, the study registered 275 events of SN (CTCAE grade 3 or 4) and 9 events of FN. During the first dd cycle, SN occurred in 33.3% and FN in 1.1% of patients. CTx delay or dose reduction due to neutropenia was required in 2.5% of patients during the 4 dd cycles with lipegfilgrastim support. Overall, 314 adverse events (AEs) were reported from 107 patients and 27 serious AEs from 21 patients. None of the SAEs was "fatal," and CTCAE grade was mostly (89.6%) assessed as "1" or "2." According to the treating physicians, 99.3% of all patients benefitted from lipegfilgrastim prophylaxis, and tolerability was mostly rated "very good" or "good." Conclusion: These results suggest that primary lipegfilgrastim prophylaxis is effective and safe in clinical routine and is beneficial in primary breast cancer patients undergoing dd/idd-ETC CTx. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.

Author

Thill, Marc, Lüftner, Diana, Kolberg-Liedtke, Cornelia, Albert, Ute-Susann, Banys-Paluchowski, Maggie, Bauerfeind, Ingo, Blohmer, Jens-Uwe, Budach, Wilfried, Dall, Peter, Fallenberg, Eva Maria, Fasching, Peter A., Fehm, Tanja, Friedrich, Michael, Gerber, Bernd, Gluz, Oleg, Harbeck, Nadia, Heil, Jörg, Huober, Jens, Jackisch, Christian, and Kreipe, Hans-Heinrich

Subjects
BREAST cancer prognosis, BREAST tumor diagnosis, THERAPEUTIC use of antineoplastic agents, DRUG efficacy, IMMUNE checkpoint inhibitors, GENETIC mutation, PROTEIN kinase inhibitors, CANCER chemotherapy, ONCOGENES, EPIDERMAL growth factor receptors, METASTASIS, ANTINEOPLASTIC agents, MEDICAL protocols, BONE tumors, AROMATASE inhibitors, BREAST tumors, HORMONE receptor positive breast cancer, PALLIATIVE treatment
Abstract

The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2022 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Dihydropyrimidine dehydrogenase testing prior to treatment with 5-Fluorouracil, Capecitabine, and Tegafur

Author

Wörmann, Bernhard (Prof. Dr. med.), Bokemeyer, Carsten (Prof. Dr. med.), Burmeister, Thomas (PD Dr. Dr. med.), Köhne, Claus-Henning (Prof. Dr. med.), Schwab, Matthias (Prof. Dr. med.), Arnold, Dirk (Prof. Dr. med.), Blohmer, Jens-Uwe, Borner, Markus, Brucker, Sara (Dr. med.), Cascorbi, Ingolf (Prof. Dr. med. Dr. rer. nat.), Decker, Thomas (Prof. Dr. med.), Wit, Maike de, Dietz, Andreas (Prof. Dr. med.), Einsele, Hermann (Prof. Dr. med.), Eisterer, Wolfgang, Folprecht, Gunnar (PD Dr. med.), Hilbe, Wolfgang (Prim. Univ.-Prof. Dr.), Hoffmann, Jürgen (Prof. Dr. med. Dr. med. dent.), Knauf, Wolfgang (Dr. med.), Kunzmann, Volker (Prof. Dr. med.), Largiadèr, Carlo R., Lorenzen, Sylvie (Dr. med.), Lüftner, Diana (Prof. Dr. med.), Moehler, Markus (Prof. Dr. med.), Nöthen, Markus M. (Prof. Dr.), Pox, Christian P. (Prof. Dr. med.), Reinacher-Schick, Anke Claudia (Prof. Dr. med.), Scharl, Anton, Schlegelberger, Brigitte (Prof. Dr. med.), Seufferlein, Thomas (Prof. Dr. med.), Sinn, Marianne (Prof. Dr. med.), Stroth, Matthias (Dr. med.), Tamm, Ingo (Dr. med.), Trümper, Lorenz, Wilhelm, Martin (Prof. Dr. med.), Wöll, Ewald (Prim. Univ.-Prof. Dr.), and Hofheinz, Ralf-Dieter (Prof. Dr. med.)

Subjects
ddc:610
Abstract

\(\bf Background:\) 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side effects and the treatment-related mortality rate is 0.2–1.0%. \(\bf Summary:\) Among other risk factors associated with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for the metabolism of FU, is well known. This is due to variants in the DPD gene (DPYD). Up to 9% of European patients carry a DPD gene variant that decreases enzyme activity, and DPD is completely lacking in approximately 0.5% of patients. Here we describe the clinical and genetic background and summarize recommendations for the genetic testing and tailoring of treatment with 5-FU derivatives. The statement was developed as a consensus statement organized by the German Society for Hematology and Medical Oncology in cooperation with 13 medical associations from Austria, Germany, and Switzerland. \(\bf Key Messages:\) (i) Patients should be tested for the 4 most common genetic DPYD variants before treatment with drugs containing FU. (ii) Testing forms the basis for a differentiated, risk-adapted algorithm with recommendations for treatment with FU-containing drugs. (iii) Testing may optionally be supplemented by therapeutic drug monitoring.

Published
2020

49. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

Author

Michel, Laura L., Hartkopf, Andreas D., Fasching, Peter A., Kolberg, Hans-Christian, Hadji, Peyman, Tesch, Hans, Häberle, Lothar, Ettl, Johannes, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Belleville, Erik, Volz, Bernhard, Hübner, Hanna, Wimberger, Pauline, Hielscher, Carsten, Mundhenke, Christoph, Kurbacher, Christian, Wuerstlein, Rachel, Untch, Michael, Overkamp, Friedrich, Huober, Jens, Janni, Wolfgang, Taran, Florin-Andrei, Lux, Michael P., Wallwiener, Diethelm, Brucker, Sara Y., Schneeweiss, Andreas, and Fehm, Tanja N.

Subjects
musculoskeletal diseases, advanced breast cancer, Neoplasm metastasis, T-DM1, Metastase, Trastuzumab, chemotherapy, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, HER2/neu, lcsh:RC254-282, Article, metastatic, HER2 c-erbB2, trastuzumab, pertuzumab, Brustkrebs, Breast neoplasms, Drug therapy, ddc:610, Chemotherapie, DDC 610 / Medicine & health
Abstract

The approval of trastuzumab emtansine (T-DM1) was conducted without pertuzumab as previous therapy. Efficacy data on T-DM1 following pertuzumab treatment are therefore limited. This study explores this issue in a real-world setting. Within the prospective PRAEGNANT (Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Advanced Setting) metastatic breast cancer registry (NCT02338167), patients in all therapy lines receiving any kind of treatment were eligible for inclusion. This report describes patient characteristics and progression-free survival (PFS) in human epidermal growth factor receptor 2 (HER2)-positive patients receiving T-DM1 after pertuzumab treatment. Seventy-six patients were identified, 39 of whom received T-DM1 as second-line therapy, 25 as third-line, and 12 as fourth-line therapy or higher. Pertuzumab was mostly administered as a first-line treatment (n = 61, 80.3%). The median PFS in all patients was 3.5 months (95% CI: 2.8&ndash, 7.8), in second-line treatment, 7.7 months (95% CI: 2.8&ndash, 11.0), in third-line, 3.4 months (95% CI: 2.3&ndash, not reached (NR)), and in fourth-line therapy or higher, 2.7 months (95% CI: 1.2&ndash, NR). T-DM1 was mainly administered second-line after pertuzumab, but also in more heavily pretreated patients. The PFS in higher therapy lines appears to be shorter than in second-line.

Published
2020

50. RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole : Results of the third interim analysis

Author

Hartkopf, Andreas, Nusch, Arnd, Decker, Thomas, Reinisch, Mattea, Heinrich, Bernhard J, Kurbacher, Christian, Fuchs, Roswitha, Tesch, Hans, Krabisch, Petra, Brucker, Sara, Fehm, Tanja N, Janni, Wolfgang, Kümmel, Sherko, Lüftner, Diana, Schneeweiss, Andreas, Schuler, Martin, Voges, Claudia, Schubert, Jörg, and Fasching, Peter A

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster Abstract

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results